Evidence map›Paper›PMID 34355333›Full record

ArticleAnnals of surgical oncology2022

PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.

Yushi Nagaki, Satoru Motoyama, Yusuke Sato, Akiyuki Wakita, Hiromu Fujita, Kohei Kemuriyama, Yoshihiro Sasaki, Kazuhiro Imai, Eri Maeda, Yoshihiro Minamiya

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yushi NagakiDivision of Esophageal Surgery, Akita University Hospital, Akita, Japan. standoffdatta10@yahoo.co.jp.
Satoru MotoyamaDivision of Esophageal Surgery, Akita University Hospital, Akita, Japan.
Yusuke SatoDivision of Esophageal Surgery, Akita University Hospital, Akita, Japan.
Akiyuki WakitaDivision of Esophageal Surgery, Akita University Hospital, Akita, Japan.
Hiromu FujitaDivision of Esophageal Surgery, Akita University Hospital, Akita, Japan.
Kohei KemuriyamaDivision of Esophageal Surgery, Akita University Hospital, Akita, Japan.
Yoshihiro SasakiDivision of Esophageal Surgery, Akita University Hospital, Akita, Japan.
Kazuhiro ImaiDepartment of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Eri MaedaEnvironmental Health Science and Public Health, Akita University Graduate School of Medicine, Akita, Japan.
Yoshihiro MinamiyaDepartment of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
Akita University Hospital · JPAkita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with

methodsOf 129 TESCC patients with clinical lymphatic metastasis who underwent curative-intent esophagectomy after NACRT between 2010 and 2018, 97 who received PET before and after NACRT were enrolled in the study. The study defined lymph nodes with a maximum standardized uptake value (SUV

resultsNo significant difference in survival was detected between the cPET-N(+) and cPET-N(-) patients. However, the CRT-cPET-N(-) patients had significantly better 5-year overall survival (OS) and disease-specific survival (DSS) than the CRT-cPET-N (+) patients. The PET-N responders had significantly better 5-year OS and DSS than the PET-N non-responders, and PET-N response was an independent prognostic factor for 5-year DSS.

conclusionThe PET-N response is a highly predictive prognostic marker for TESCC patients who undergo NACRT followed by esophagectomy. The PET-N response may help clinicians to establish a strategy for perioperative treatments that improves survival for patients with lymph node metastasis in TESCC.

Indexed as

Carcinoma, Squamous CellEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaChemoradiotherapyEsophagectomyFluorodeoxyglucose F18HumansLymph NodesNeoadjuvant TherapyPrognosisRadiopharmaceuticalsTreatment OutcomeFluorodeoxyglucose F18RadiopharmaceuticalsESCCEsophagectomyFDG-PETNACRTPET-N

Identifiers

PMID34355333
OpenAlexW3190035131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.